On March 27, 2026, Q32 Bio Inc. announced that it has entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. This agreement allows the company to offer and sell shares of its common stock, par value $0.0001 per share, through Cantor Fitzgerald as the sales agent. The offering is part of a shelf registration statement on Form S-3, which was filed with the SEC on April 11, 2025, and declared effective on April 21, 2025. The company plans to raise up to $14.2 million through this at-the-market offering program.

Under the terms of the Sales Agreement, Q32 Bio will determine the parameters for the sale of shares, including the number of shares to be sold and the timing of the sales. The sales agent will sell the shares by any method deemed appropriate, including transactions on The Nasdaq Capital Market. The company is not obligated to sell any shares under this agreement, and either party may suspend or terminate the offering upon notice.

The company will pay Cantor Fitzgerald a cash commission of 3.0% of the gross proceeds from the sale of the shares. Additionally, Q32 Bio has agreed to provide customary indemnification and contribution rights to the sales agent and will reimburse certain expenses incurred in connection with the Sales Agreement. This move is seen as a strategic effort to bolster the company's liquidity and financial flexibility, allowing it to fund ongoing operations and potential growth initiatives.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.